Iovance Biotherapeutics Inc (NAS:IOVA)
$ 7.78 -0.36 (-4.42%) Market Cap: 2.18 Bil Enterprise Value: 2.01 Bil PE Ratio: 0 PB Ratio: 3.20 GF Score: 35/100

Iovance Biotherapeutics Inc at Jefferies Cell Therapy Summit Transcript

Oct 06, 2020 / 07:00PM GMT
Release Date Price: $28.1 (-12.35%)
Biren N. Amin
Jefferies LLC, Research Division - MD and Senior Equity Research Analyst

Well, welcome, everyone, to Jefferies Cell Therapy Summit. We're about almost done here on day 2. We've got Iovance Biotherapeutics, which has had, I guess, a news-filled last 12 hours. And so we've got CEO Maria Fardis to give us an overview of Iovance and I'm sure you'll give us the latest update. So Maria, please take it away.

Maria Fardis
Iovance Biotherapeutics, Inc. - CEO, President & Director

Excellent. Thank you so much. Good afternoon. Thank you, Biren, for hosting us. I will be talking about investigating the power of tumor-infiltrating lymphocytes for treatment of cancers today. We're a public company. I draw your attention to our forward-looking statements.

In terms of recent updates, maybe I'll start with saying what information we have talked about in 2020 and then the latest update that we have provided to The Street yesterday. We've been talking about providing data in terms of -- we presented our melanoma data at ASCO as an oral presentation.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot